Olopatadine: A drug for allergic conjunctivitis targeting the mast cell

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 6, 2010, Pages 969-981

  Leonardi, Andrea ^a   Quintieri, Luigi ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Allergic conjunctivitis; Conjunctival allergen challenge; Histamine; Mast cell stabilization; Mast cells; Olopatadine

Indexed keywords

ANTAZOLINE; ANTIHISTAMINIC AGENT; AZELASTINE; CROMOGLYCATE DISODIUM; EPINASTINE; IMMUNOGLOBULIN E; KETOROLAC; KETOTIFEN; KETOTIFEN FUMARATE; LEVOCABASTINE; LODOXAMIDE; LODOXAMIDE TROMETAMOL; LORATADINE; N ACETYLASPARTYLGLUTAMIC ACID; NEDOCROMIL SODIUM; OLOPATADINE; PATADAY; PEMIROLAST; PHENIRAMINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CELL ACTIVATION; CHEMOSIS; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONJUNCTIVA EPITHELIUM; CONJUNCTIVAL REDNESS; CONJUNCTIVITIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; HISTAMINE RELEASE; HUMAN; MAST CELL; NONHUMAN; OCULAR PRURITUS; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; RHINOCONJUNCTIVITIS; TISSUE DISTRIBUTION; URINARY EXCRETION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-ALLERGIC AGENTS; CONJUNCTIVITIS, ALLERGIC; DIBENZOXEPINS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HISTAMINE RELEASE; HUMANS; MAST CELLS; OPHTHALMIC SOLUTIONS; TREATMENT OUTCOME;

EID: 77949911611     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003694643     Document Type: Review

References (100)

1. Berger W, Abelson MB, Gomes PJ, et al. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Ann Allergy Asthma Immunol 2005;95:361-371
2. Key B. Allergy and allergic diseases. Part I. N Engl J Med 2001;344:30-37
3. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005;115:118-122
4. Lanier B. Allergic rhinitis: selective comparison of the pharmaceutical options for management. Allergy Asthma Proc 2007;28:16-19
5. Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as 'tunable' effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005;23:749-786
6. Blank U, Rivera J. The ins and outs of IgE-dependent mast cell exocytosis. Trends Immunol 2004;25:266-273
7. Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol 2004;4:787-799
8. Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J Allergy Clin Immunol 2006;117:1214-1225
9. Cook EB, Stahl JL, Barney NP, Graziano FM. Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation. Curr Drug Targets Inflamm Allergy 2000;1:167-180
10. Allansmith MR, Greiner JV, Baird RS. Number of inflammatory cells in the normal conjunctiva. Am J Ophthalmol 1978;86:250-259
11. Morgan SJ, Williams JH, Walls AF, et al. Mast cell numbers and staining characteristics in the normal and allergic human conjunctiva. J Allergy Clin Immunol 1991;87:111-116
12. Anderson DF, MacLeod JD, Baddeley SM, et al. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leukocyte infiltration. Clin Exp Allergy 1997;27:1060-1066
13. Irani AM, Butrus SI, Tabbara KF, Schwartz LB. Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol 1990;86:34-40
14. Anderson DF, Zhang S, Bradding P, et al. The relative contribution of mast cell subsets to conjunctival T(H)2-like cytokines. Invest Ophthalmol Vis Sci 2001;42:995-1001
15. Leonardi A. Role of histamine in allergic conjunctivitis. Acta Ophthalmol Scand 2000;230(Suppl):18-21
16. Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol 2005;5:437-440
17. Miller S, Cook E, Graziano F, et al. Human conjunctival mast cell responses in vitro to various secretagogues. Ocul Immunol Inflamm 1996;4:39-49
18. Morgan SJ, Williams JH, Walls AF, Holgate ST. Mast cell hyperplasia in atopic keratoconjunctivitis. An immunohistochemical study. Eye 1991;5:729-735
19. Cook EB, Stahl JL, Miller ST, et al. Isolation of human conjunctival mast cells and epithelial cells: tumor necrosis factor-alpha from mast cells affects intercellular adhesion molecule 1 expression on epithelial cells. Invest Ophthalmol Vis Sci 1998;39:336-343
20. Stahl JL, Cook EB, Graziano FM, Barney NP. Human conjunctival mast cells: expression of Fc epsilonRI, c-kit, ICAM-1, and IgE. Arch Ophthalmol 1999;117:493-497
21. Miyazaki D, Nakamura T, Toda M, et al. Macrophage inflammatory protein-1alpha as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions. J Clin Invest 2005;115:434-442
22. Galatowicz G, Ajayi Y, Stern ME, Calder VL. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo. Clin Exp Allergy 2007;37:1648-1656
23. Kumagai N, Fukuda K, Fujitsu Y, et al. Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis. Prog Retin Eye Res 2006;25:165-187
24. Abu El-Asrar AM, Struyf S, Van Damme J, Geboes K. Role of chemokines in vernal keratoconjunctivitis. Int Ophthalmol Clin 2003;43:33-39
25. Leonardi A, Jose P, Zhan, Calder V. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 2003;110:487-492
26. Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy 2006;36:777-784
27. Montan PG, Scheynius A, van der Ploeg I. Similar T helper Th2-like cytokine mRNA expression in vernal keratoconjunctivitis regardless of atopic constitution. Allergy 2002;57:436-441
28. Undem BJ, Kajekar R, Hunter DD, Myers AC. Neural integration and allergic disease. J Allergy Clin Immunol 2000;106(5 Suppl):213-220
29. Diebold Y, Rios JD, Hodges RR, et al. Presence of nerves and their receptors in mouse and human conjunctival goblet cells. Invest Ophthalmol Vis Sci 2001;42:2270-2282
30. Motterle L, Diebold Y, Enriquez de Salamanca A, et al. Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis. Arch Ophthalmol 2006;124:462-468
31. Leonardi A. Emerging drugs for ocular allergy. Expert Opin Emerg Drugs 2005;10:505-520
32. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990;108:84-88
33. Leonardi A, Smith LM, Fregona IA, Secchi AG. Tear histamine and histaminase during the early (EPR) and late (LPR) phases of the allergic reaction and the effect of lodoxamide. Eur J Ophthalmol 1996;6:106-112
34. Butrus SI, Ochsner KI, Abelson MB, Schwartz LB. The level of tryptase in human tears. An indicator of activation of conjunctival mast cells. Ophthalmology 1990;97:1678-1683
35. Bacon AS, Ahluwalia P, Irani AM, et al. Tear and conjunctival changes during the allergen-induced early-and late-phase responses. J Allergy Clin Immunol 2000;106:948-954
36. Cipriandi G, Buscaglia S, Pesce GP, et al. Allergic subjects express intercellular adhesion molecule 1 (ICAM-1 or CD 54) on epithelial cells of conjunctiva after allergen challenge. J Allergy Clin Immunol 1993;91:783-792
37. Abelson MB, Pratt S, Mussoline JE, Townsend D. One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears. Clin Ther 2003;25:2070-2084
38. Lim LL, Hoang L, Wong T, et al. Intravital microscopy of leukocyte-endothelial dynamics using the Heidelberg confocal laser microscope in scleritis and allergic conjunctivitis. Mol Vis 2006 12:1302-1305
39. Yanni JM, Miller ST, Gamache DA, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol 1997;79:541-545
40. Sharif NA, Xu SX, Miller ST, et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996;278:1252-1261
41. Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther 1996;12:401-407
42. Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/ antihistaminic agent. J Ocul Pharmacol Ther 1996;12:389-400
43. Miyake K, Horikoshi K, Ikeda Y, et al. Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs. Jpn J Pharmacol 2001;85:453-456
44. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits TNFalpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol 2000;84:504-508
45. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann Allergy Asthma Immunol 2001;87:424-429
46. Schoch C. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen. J Ocul Pharmacol Ther 2003;19:75-81
47. Kempuraj D, Huang M, Kandere K, et al. Azelastine is more potent than olopatadine in inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Ann Allergy Asthma Immunol 2002;88:501-506
48. Kempuraj D, Huang M, Kandere-Grzybowska K, et al. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol 2003;132:231-239
49. Chand N, Pillar J, Diamantis W, Sofia RD. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs. Agents Actions 1985;16:318-322
50. Kamei C, Akagi M, Mio M, et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: elucidation of the mechanism for histamine release inhibition. Immunopharmacol Immunotoxicol 1992;14:191-205
51. Brockman HL, Momsen MM, Knudtson JR, et al. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul Immunol Inflamm 2003;11:247-268
52. Cook EB, Stahl JL, Sedgwick JB, et al. The promotion of eosinophil degranulation and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells. Ann Allergy Asthma Immunol 2004;92:65-72
53. Cook EB, Stahl JL, Brooks AM, et al. Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment. Invest Ophthalmol Vis Sci 2006;47:3423-3429
54. Fukuishi N, Matsuhisa M, Shimono T, et al. Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils. Jpn J Pharmacol 2002;88:463-466
55. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999;117:643-647
56. Matsubara M, Tamura T, Ohmori K, Hasegawa K. Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+-dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades. Biochem Pharmacol 2005;69:433-449
57. Tokura Y, Kobayashi M, Ito T, et al. Anti-allergic drug olopatadine suppresses murine contact hypersensitivity and downmodulates antigen-presenting ability of epidermal Langerhans cells. Cell Immunol 2003;224:47-54
58. Tamura T, Matsubara M, Hasegawa K, et al. Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity. Clin Exp Allergy 2005;35:97-103
59. Furukawa H, Takahashi M, Nakamura K, Kaneko F. Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis. J Dermatol Sci 2004;36:165-172
60. Abelson MB. A review of olopatadine for the treatment of ocular allergy. Expert Opin Pharmacother 2004;5:1979-1994
61. Rosenwasser LJ, O'Brien T, Weyne J. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr Med Res Opin 2005;21:1377-1387
62. Brodsky M, Berger WE, Butrus S, et al. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model. Eye Contact Lens 2003;29:113-116
63. Leonardi A, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 2003;25:2539-2552
64. Abelson MB, Greiner JV. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Curr Med Res Opin 2004;20:1953-1958
65. Butrus S, Greiner JV, Discepola M, Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2000;22:1462-1472
66. Deschenes J, Discepola M, Abelson MB. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scan 1999;77(Suppl 228):47-52
67. Berdy GJ, Spangler DL, Bensch G, et al. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2000;22:826-833
68. Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2001;23:1272-1280
69. Lanier BQ, Finegold I, D'Arienzo P, et al. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin 2004;20:1227-1233
70. Finegold I, Granet DB, D'Arienzo PA, Epstein AB. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. Clin Ther 2006;28:1630-1638
71. Abelson MB, Turner D. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. Clin Ther 2003;25:931-947
72. Katelaris CH, Ciprandi G, Missotten L, et al. International Olopatadine Study Group. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 2002;24:1561-1575
73. Ciparandi G, Turner D, Gross RD. Double-masked, randomized, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis. Curr Ther Res 2004;65:186-199
74. Guest JF, Clegg JP, Smith AF. Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK. Curr Med Res Opin 2006;22:1777-1785
75. Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand 2000;230(Suppl):52-55
76. Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Curr Med Res Opin 2004;20:1167-1173
77. Lanier BQ, Gross RD, Marks BB, et al. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Ann Allergy Asthma Immunol 2001;86:641-648
78. Corum I, Yeniad B, Bilgin LK, Ilhan R Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density. J Ocul Pharmacol Ther 2005;21:400-405
79. Theoharides TC, Sieghart W, Greengard P, Douglas WW. Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. Science 1980;207:80-82
80. Calonge M, Montero JA, Herreras JM, et al. Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy. Ann Allergy Asthma Immunol 1996;77:124-130
81. Bissonnette EY, Enciso JA, Befus AD. Interferon and antiallergic drug regulation of histamine and tumor necrosis factor-alpha in rat mast cell subsets. Int Arch Allergy Immunol 1995;107:156-157
82. Pearce FL, Al-Laith M, Bosman L, et al. Effects of sodium cromoglycate and nedocromil sodium on histamine secretion from mast cells from various locations. Drugs 1989;37(Suppl 1):37-43;discussion 69-77
83. Okayama Y, Benyon RC, Rees PH, et al. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy 1992;22:401-409
84. Fujimiya H, Nakashima S, Miyata H, Nozawa Y. Effect of a novel antiallergic drug, pemirolast, on activation of rat peritoneal mast cells: inhibition of exocytotic response and membrane phospholipid turnover. Int Arch Allergy Appl Immunol 1991;96:62-67
85. Yanagihara Y, Kasai H, Matsui S, Ninomiya K. Immunopharmacological studies on TBX, a new antiallergic drug (3). Inhibitory effects on histamine release from lung fragments and bronchoconstriction in guinea pigs. Jpn J Pharmacol 1989;51:83-92
86. Johnson HG, Sheridan AQ. The characterization of lodoxamide, a very active inhibitor of mediator release, in animal and human models of asthma. Agents Actions 1986;18:301-305
87. Yanni JM, Weimer LK, Glaser RL, et al. Effect of lodoxamide on in vitro and in vivo conjunctival immediate hypersensitivity responses in rats. Int Arch Allergy Immunol 1993;101:102-106
88. Bonini S, Schiavone M, Bonini S, et al. Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis. Ophthalmology 1997;104:849-853
89. Secchi AG, Angi MR, Corbetta C. Pharmacological modulation of histamine release from choroidal mast cells induced by N-acetyl-aspartil-glutamic acid (MgNAAGA). Farmaco [Prat] 1987;42:319-324
90. Bouhlal H, Blondin C, Haeffner-Cavaillon N, Goldschmidt P. N acetyl-aspartyl glutamic acid (NAAGA) inhibits the adhesion of leukocytes to activated endothelial cells and down-modulates the cytokine-induced expression of adhesion molecules. J Fr Ophtalmol 2002;25:993-1000
91. Goldschmidt P, Couturier C, Haeffner-Cavaillon N, et al. Effects of non-steroidal antiallergic eyedrops on the complement-mediated histamine release from human cells. Ocul Immunol Inflamm 1997;5:11-17
92. Truneh A, White JR, Pearce FL. Effect of ketotifen and oxatomide on histamine secretion from mast cells. Agents Actions 1982;12:206-209
93. Sekardi L, Friedberg KD. Inhibition of immunological histamine release from guinea pig lungs and other organs by mepyramine, ketotifen, and picumast in vivo. Arzneimittelforschung 1989;39:1331-1335
94. Lytinas M, Kempuraj D, Huang M, et al. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists. Int Arch Allergy Immunol 2003;130:224-231
95. Lytinas M, Kempuraj D, Huang M, et al. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine. Allergy Asthma Proc 2002;23:45-51
96. Owen CG, Shah A, Henshaw K, et al. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. Br J Gen Pract 2004;54:451-456
97. Abelson MB, Gomes PJ. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin Drug Metab Toxicol 2008;4:453-461
98. Abelson MB, Spangler DL, Epstein AB, et al. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Curr Eye Res 2007;32:1017-1022
99. Scoper SV, Berdy GJ, Lichtenstein SJ, et al. Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. Adv Ther 2007;24:1221-1232
100. Chand N, Pillar J, Diamantis W, et al. Inhibition of calcium ionophore (A23187)-stimulated histamine release from rat peritoneal mast cells by azelastine: implications for its mode of action. Eur J Pharmacol 1983;96:227-233